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Primary Sjögren’s syndrome (pSS) is associated with polymorphisms and mRNA
expression profiles that are indicative of an exaggerated innate and type I IFN immune
response. Excessive activation potential of signaling pathways may play a role in this
profile, but the intracellular signaling profile of the disease is not well characterized.
To gain insights into potentially dysfunctional intracellular signaling profiles of pSS
patients we conducted an exploratory analysis of MAPK/ERK and JAK/STAT signaling
networks in peripheral blood mononuclear cells (PBMC) from 25 female pSS patients
and 25 female age-matched healthy donors using phospho-specific flow cytometry. We
analyzed unstimulated samples, as well as samples during a 4 h time period following
activation of Toll-like receptor (TLR) 7 and 9. Expression levels of MxA, IFI44, OAS1,
GBP1, and GBP2 in PBMC were analyzed by real-time PCR. Cytokine levels in plasma
were determined using a 25-plex Luminex-assay. Principal component analysis (PCA)
showed that basal phosphorylation profiles could be used to differentiate pSS patients
from healthy donor samples by stronger intracellular signaling pathway activation in NK
and T cells relative to B cells. Stimulation of PBMC with TLR7 and −9 ligands showed
significant differences in the phosphorylation profiles between samples from pSS patients
and healthy donors. Including clinical parameters such as extraglandular manifestations
(EGM), we observed stronger responses of NF-κB and STAT3 S727 in B cells from
EGM-negative patients compared to EGM-positive patients and healthy controls. Plasma
cytokine levels were correlated to the basal phosphorylation levels in these patients. In
addition, 70% of the patients had a positive IFN score. These patients differed from the
IFN score negative patients regarding their phosphorylation profiles and their plasma
cytokine levels. In conclusion, we here report increased signaling potentials in peripheral
B cells of pSS patients in response to TLR7 and −9 stimulation through STAT3 S727
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and NF-κB that correlate with a type I IFN signature. Induction of these pathways could
contribute to the generation of a type I IFN signature in pSS. Patients displaying elevated
potentiation of STAT3 S727 and NF-κB signaling could therefore benefit from therapies
targeting these pathways.
Keywords: Sjögren’s syndrome, extraglandular manifestations, autoantibodies, phosphoflow, Toll-like receptors,
type I interferon
INTRODUCTION
Sjögren’s syndrome (SS) is a systemic autoimmune disease
characterized by lymphocytic infiltrates of the salivary and
lacrimal glands. The hallmarks of the disease are dryness of
the mouth (xerostomia) and the eyes (keratoconjunctivitis sicca)
(1, 2). This dryness and other clinical manifestations result
in a significant decrease in quality of life. Currently there is
no cure or effective disease modifying treatment for SS, with
management of the disease based on the relief of symptoms.
The lack of effective treatments is linked to the pathogenic
complexity of the disease, with genetic predisposition, hormonal,
and environmental factors all contributing to disease etiology
and pathogenesis. While almost all SS patients display abnormal
tear and/or saliva secretion (3), there is significant heterogeneity
in the disease manifestations, pathology and clinical course.
This heterogeneity may reflect distinct patient subgroups with
unique pathophysiologic mechanisms (4). For example, Sjögren’s
syndrome can present with a wide range of extraglandular
manifestations (EGM) including fatigue and constitutional,
musculoskeletal, articular, cutaneous, pulmonary, liver, and
kidney involvement, as well as neuropathies and lymphomas (5).
B cell hyperactivity is also a common feature of SS. It canmanifest
as hypergammaglobulinaemia and presence of autoantibodies
including anti-Sjögren’s syndrome A (SSA) and anti-Sjögren’s
syndrome B (SSB) (5) often preceding clinical symptoms (6).
Aspects of SS pathogenesis that have gained considerable
attention during recent years are abnormal cytokine production
and genetic associations. Of prominent interest are features
associated with type I interferon (IFN). The type I IFN family
consists of multiplemembers including IFN-α and β, and they are
involved in various biological functions including defense against
viral or bacterial infection, immune-modulation, and negative
regulation of proliferation (7). An activated type I IFN system
known as the interferon signature plays an important role in
different autoimmune diseases, amongst them pSS (7, 8). In pSS
patients, the interferon signature is associated with higher disease
activity index scores (9).
It has been speculated that the initiating factor in the activated
type I IFN response is a genetically determined exaggerated
innate immune response against inappropriately overexpressed
endogenous or exogenous danger signals. Extracellular nucleic
acids present during viral infections, for example, can induce type
I IFN production through interactions of extracellular nucleic
acid with endosomal receptors, including TLR3, TLR7, and TLR9
(7). In SS it has been speculated that expression of danger
signals resulting from transient or persistent viral infection of
epithelial cells leads to continuous activation of TLR signaling
eventually contributing to SS pathogenesis (7). Interestingly, a
number of infectious agents including Epstein-Barr virus, human
T-lymphotropic virus type 1, hepatitis C virus and enterovirus
have been reported as potential initiators of glandular lesions in
SS patients (7).
Dysfunctional intracellular signaling mechanisms may
influence the immunological response of a cell to a given
stimulus, affecting transduction of a given signal and resulting
in aberrant gene expression. We have previously shown
that patients with pSS have an altered response of PBMC to
IFN stimulation (10). Interestingly, several genetic variants
associated with SS function in downstream signaling from
TLRs or their regulation, including IRF5 (11, 12), IL-10
(13), IκBα (14), TNFAIP3 interacting protein 1 (TNIP1)
(12), and OAS1 (15). Potentiation, chronic activation or
dysregulation of TLR signaling pathways could lead to
exaggerated production of type I IFN and contribute
to the type I IFN signature and disease pathogenesis.
However, not much is known about TLR signaling in
patients with pSS.
In this study, we characterized intracellular signaling
pathways including those downstream from TLR7 and −9
receptor activation in PBMC by phospho-specific flow cytometry
(phosphoflow) (16). We focused here on direct targets of TLR
signaling such as ERK/MAPK as well as epitopes activated
upon IFN signaling such as JNK/STAT. Increased induction of
phosphorylation of STAT3 S727 and NF-κB was observed in
B cells from pSS patients following TLR7 and −9 stimulation
compared to B cells from healthy donors. The activation was
shown to be increased in patients with SSA autoantibodies and
patients without extraglandular manifestation. The increased
responses following TLR7 and −9 stimulation through STAT3
S727 and NF-κB in B cells were associated with increased
expression of three genes upregulated in response to type I IFN
(MxA, IFI44, OAS1) but not type II IFN inducible genes (GBP1
and GBP2). Plasma cytokine levels were different in SSA+ and
SSA– patients and correlated with basal phosphorylation levels
of several phospho-epitopes in patient subgroups. In conclusion,
this study provides support that enhanced responses through
TLR7 and −9 may play a role in the induction of a type I IFN
signature observed in pSS patients indicating viral infections
as potential trigger of the disease. Alternatively, induced
expression of type I IFN inducible genes may potentiate TLR7
and −9 responses. Patients displaying elevated potentiation
of these pathways may therefore benefit from therapies
targeting these pathways.
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MATERIALS AND METHODS
Blood Sampling
Peripheral blood from patients with pSS was collected in
Lithium-heparin tubes (BD diagnostics) at the Department of
Rheumatology, Haukeland University Hospital, Bergen, Norway.
Blood from healthy age- and gender-matched donors was
collected at the blood bank at the Haukeland University Hospital
in Bergen, Norway. PBMC were isolated by density gradient
centrifugation with lymphoprepTM (Axis-Shield, Oslo, Norway)
and cryopreserved as described previously (17). Plasma was
aliquoted and stored at −70◦C, and PBMC were stored at
−150◦C for ∼12–16 months. All patients fulfilled the pSS
American-European Consensus group (AECG) criteria (18) and
displayed no additional autoimmune diseases or lymphoma. An
overview of the cohort is shown in Table 1. The study was
approved by the regional ethical committee (#2009/686). All
participants provided written informed consent.
Routine Laboratory Assays
Identification of anti-Ro/SSA and anti-La/SSB, other antinuclear
antibodies (ANA), erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), and extraglandular manifestations were
obtained as part of routine clinical investigation at time of blood
sampling. SSA, SSB, and ANA were reported as either present or
absent, while other serum and blood parameters were reported as
continuous values. Extraglandular manifestations were defined as
disease features outside surface exocrine glands.






Age, median (range) years 56 (33–73) 54 (42–70)
CLINICAL FEATURES (PATIENTS)
SSA antibodies (%) 19 (76)
SSB antibodies (%) 12 (48)
SSA and SSB antibodies (%) 12 (48)
ANA (%) 19 (76)
Positive Schirmer’s test (tear flow <5
mm/5min) (%); n = 24
14 (58.3)
Focus score† ≥ 1 (%); n = 14 10 (71.4)
ESR, high levels†† 5 (20)
CRP high levels (≥5 mg/L) 2 (8)




Continuous data is expressed as median. Categorical data is expressed as frequency and
percentage.
†
Focus score indicates the number of inflammatory foci containing more than
50 mononuclear cells per 4 mm2 biopsy tissue;
††
Age and gender dependent. DMARDs,
disease-modifying anti-rheumatic drugs; ANA, anti-nuclear antibodies; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein.
Real-Time Quantitative PCR
Total RNA was isolated from PBMC of 20 pSS patients
and 17 healthy controls and transcribed into cDNA as
described previously (10). The following Taqman gene expression
assays were utilized: Hs00895608_m1 (MxA); Hs00973637_m1
(OAS1); Hs00951349_m1 (IFI44); Hs00977005_m1 (GBP1);
Hs00894837_m1 (GBP2); Hs03928990_g1 (18S rRNA) (all
Thermo Fisher Scientific, Waltham, USA). All PCR reactions
were run in duplicates on a Light Cycler 480 (Roche Diagnostics,
Oslo, Norway). 18S rRNA was used as reference gene, and
relative expression levels were calculated as 2−1Ct. The IFN score
was calculated according to Feng et al. (19) by standardizing
expression levels using mean and SD of the healthy controls for




gene ipSS −mean gene iCtr
SD (gene iCtr)
where i = each of the 3 type I IFN-inducible genes (MxA, IFI44,
OAS1), gene ipSS = the gene expression level in each pSS patient,
and gene iCtr = the gene expression in controls. To set a threshold,
3× SD of healthy controls was utilized.
Antibodies Used for Flow Cytometry
The following phospho-specific monoclonal antibodies were
used in 3 different panels during the flow cytometry protocol
described previously (17): Alexa Fluor R©647 conjugated anti-
STAT4 (pY693, clone 38/p-STAT4, panel 1), anti-STAT 1
(pS727, clone K51-856, panel 2), and anti-STAT3 (pS727,
clone 49/p-STAT3, panel 3); PerCP-CyTM 5.5 conjugated
anti-ERK1/2 (pT202/pY204, clone 20A, panel 1), anti-STAT1
(pY701, clone 4a, panel 2), and anti-STAT3 (pY705, clone 4/P-
STAT3, panel 3); and PE-CyTM7 conjugated anti-p38 MAPK
(pT180/pY182, clone 36/p38, panel 2), and anti NF-κB p65
(pS529, clone K10-895.12.50, panel 1), anti-STAT5 (pY694, clone
47/STAT5(pY694), panel 3) (all from BD Biosciences, San Jose,
CA, USA). Cell surface markers incorporated in the assays
were BV786 conjugated anti-CD3 (clone SK7, BD HorizonTM),
Alexa Fluor R© 488 conjugated anti-CD20 (clone H1 (FB1),
BD Biosciences) and PE conjugated anti-CD56 (clone N901,
Beckmann Coulter, CA, USA).
Cell Culture and Stimulation
Before stimulation, cryopreserved PBMC were rapidly thawed
using a water bath set to 37◦C and washed once in
prewarmed X-vivo 20TM by centrifugation at 300 g for 7min.
The cells were then resuspended in prewarmed X-vivo 20TM
and rested at 37◦C at 5% CO2 for 30min before the cell
concentration was adjusted to 3 × 106 cells/ml in X-vivo 20TM.
Two hundred microliters were dispensed into 7 wells of a
Megablock R© 96 well plate (Starstedt, Nümbrecht, Germany),
along with 2 wells of a reference sample. The cells were
rested at 37◦C with 5% CO2 for 2 h. Following, the cells
were either left unstimulated or stimulated according to a
reverse time course for 15, 30, 60, 120, 180, or 240min with
a combination of TLR7 (CL097; Invivogen) and −9 ligands
(CpG type B ODN 2006 and type C ODN 2395; Invivogen,
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Carlsbad, California, USA) at 2µg/ml each. Due to limited
cell numbers and samples, time points were excluded in 2
patients, both for 60 and 120min, and 1 healthy control for 180
and 240min.
Fluorescent Cell Barcoding and
Phospho-Epitope Staining for Flow
Cytometry
PBMC were fixed by adding 16% PFA (Electron Microscopy
Sciences (Hatfield, PA, USA) warmed to 37◦C directly into the
PBMC cultures resulting in a final PFA concentration of 1.5%.
The samples were mixed thoroughly by pipetting. The cells were
fixed at RT for 10min before pelleting at 1,000 g for 5min.
The PBMC were then vigorously resuspended by vortexing in
50 µl PBS before drop wise addition of 1ml ice cold methanol
and incubation on ice for 30min. The permeabilized cells were
kept overnight at −80◦C. After washing with PBS, the PBMC
were stained according to a 3 × 3 barcoding grid (9 stimulation
conditions) using 3 levels of pacific orange (PO) and pacific blue
(PB) succinimidyl ester dyes (PB 100, 25, and 6.3 ng/ml; PO 250,
70, and 0 ng/ml; Life Technologies, Grand Island, NY, USA) for
30min in the dark at 4◦C in a volume of 1ml. Barcoded PBMC
were then washed once with staining media (PBS containing
1% BSA), and the 9 different dye concentration/combination
samples were combined into one sample. The sample was washed
and incubated with 2 µl Fc receptor block (Miltenyi Biotec,
Bergisch Gladbach, Germany) per 1 × 106 cells for 10min
on ice. Following, the sample was subdivided into 3 parts and
incubated for 30min at RT in the dark with the 3 different
antibody staining panels. An aliquot of the barcoded cells was
collected before addition of antibody as a barcoding only control.
The samples were then washed twice and re-suspended in
staining medium containing 2mM EDTA (Sigma-Aldrich) prior
to analysis.
Flow Cytometry Data Analysis
Samples were acquired on a LSRI Fortessa flow cytometer
(BD Biosciences, San Jose, CA, USA) with BDFACSDiVaTM
Software (BD Biosciences) at the Bergen Flow Cytometry Core
Facility, University of Bergen, Norway. The flow cytometer was
equipped with 407, 488, 561, and 635 nm lasers, and emission
filters for PerCP-Cy5.5 (LP: 685, BP: 695/40), Alexa Fluor-
488 (LP: 505, BP: 530/30), PE-Cy7 (LP: 750, BP: 780/60), PE
(LP: –, BP: 582/15), APC (LP: –, BP: 670–/-14), Pacific blue
(LP: –, BP:450/50), Pacific orange (LP: 570, BP: 585/42), and
BV 786 (LP: 750, BP: 780/60). The cytometer was routinely
calibrated with BD cytometer setup and tracking beads (BD
Biosciences). A minimum of 200,000 events in the intact cell
gate was collected for each sample, giving a minimum of
2,000 events per analyzed cell population (T cells, B cells,
NK cells). Flow cytometry data were analyzed in FlowJo (Tree
Star) and Cytobank (http://www.cytobank.org). A representative
gating strategy and phosphorylation profile for a single donor
is shown in Supplementary Figure S1. Cryopreserved PBMC
from a single donor with unstimulated and stimulated samples
were run in each assay as a positive control for inter-assay
normalization and assessing assay to assay variability. Median
fluorescence intensities (MdFI) for gated populations were
exported to Microsoft excel. The raw flow cytometry data for
which this article is based can be found at the flow data repository
of the International Society for Advancement of Cytometry
(20), FR-FCM-ZYED. The robustness of the flow cytometry
assay used was previously established and published, see “An
optimized multiplex flow cytometry protocol for the analysis
of intracellular signaling in peripheral blood mononuclear
cells” (17). Relevant information for repeating the experiment
as presented in “The minimum information about a Flow
Cytometry Experiment (MIFlowCyt)” (21) are provided in
Supplementary Table S1.
Cytokine Determination
Cytokine and chemokine concentrations were determined in
plasma samples using a 25-plex Luminex assay cytokine and
chemokine panel (Invitrogen, catalog number LHC0009M) and
run on a Luminex 100 System (Luminex Corporation, Austin,
TX) according to the manufacturer’s instructions.
Statistical Analysis
Generation of graphs and comparisons between categories were
done using an Unpaired Mann-Whitney test using Graphpad
Prism (version 6.05). Differences were considered statistically
significant when p ≤ 0.05. The analysis was exploratory in
nature hence no correction was made for multiple comparisons.
Principle component analysis (PCA) using Unscrambler R© X
software (Camo software) was used to reduce dimensionality of
the dataset and find clusters of patients with similar signaling
profile which could be used to differentiate between disease
status, presence of SSA autoantibodies, EGM and medication
(DMARDs and corticosteroids). PCA was performed using the
algorithm NIPALS, the data was mean centered and run with
no weighting for change of MdFI, and weighted for absolute
MdFI by dividing by standard deviation. Two methods were
used to remove “redundant” variables to simplify interpretation
and focusing subsequent analysis. First variables that described
<50% of the variation were removed from the initial PCA, than
if appropriate stepwise reduction of less significant variables with
low variable leverage was performed. Correlations were assessed
by the Spearman’s rank test, with outliers removed using robust
regression and outlier removal (ROUT) method and a ROUT
coefficient Q of 1 used.
Since most of the cytokine data did not follow a normal
distribution, Mann-Whitney U test was performed to study
significant differences between the groups, and Spearman’s
correlation was used to find any significant relationships
between the cytokines and the phosphoproteins. Degree of
correlation was determined according to the recommendation
of the British Journal of Medicine (https://www.bmj.com/
about-bmj/resources-readers/publications/statistics-square-
one/11-correlation-and-regression)—r = 0.4–0.59 (moderate),
r = 0.6–0.79 (strong), and r = 0.8–1.0 (very strong). Analysis
was done using GraphPad Prism 7 and p ≤ 0.05 was considered
to be statistically significant.
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RESULTS
PBMC From pSS Patients Display Shifts in
Phosphorylation States of Proteins
Involved in Signaling Pathways
In order to reveal possible dysfunctional intracellular
signaling mechanisms upon TLR stimulation in pSS
patients, we here analyzed MAPK/ERK and JAK/STAT
signaling networks in peripheral blood cells from female
pSS patients and female age-matched healthy donors in
unstimulated cells and upon stimulation with a combination
of TLR7 and −9 ligands. In this pilot study, we limited
our analyses to the main lymphocyte populations (T cells,
B cells, NK cells) as all have been shown to be affected by
TLR7/9 stimulation (22–24). An overview of unstimulated
and TLR stimulated measurements can be found in the
Supplementary Table S2 (T cells), Supplementary Table S3 (B
cells), and Supplementary Table S4 (NK cells).
Significant increases of basal phosphorylation in cells from
pSS patients were observed in T cells for NF-κB, P38, ERK,
STAT5, STAT1 Y701, STAT1 S727, and NK cells for P38,
STAT5, STAT1 Y701, and STAT1 S727 compared to healthy
donors. B cells showed no significant differences in basal
phosphorylation (Figure 1A).
PCA was used to concurrently relate multiple basal signaling
states to various clinical parameters such as production of
SSA autoantibodies, presence of extraglandular manifestations
(EGM) and medication (DMARDs and corticosteroids)
within the patient cohort (Figures 1B–F). Using basal
phosphorylation levels, pSS patients could be separated
from healthy donors (Figure 1C). Spatial groupings indicated
closer similarities within the pSS and healthy donor cohorts
than between the groups. Separation of pSS and healthy
donor samples was primarily along PC2 which explained
29% of the variation. Examination of the loading plot
(Figure 1B) indicated differences between basal signaling
phenotype of pSS patients and healthy donors, with pSS
patients showing weaker basal pathway activation in B cells
relative to NK and T cells compared to healthy donor cells.
No groupings were shown along PC1 which explained
42% of the variation. Including clinical parameters in
the analysis, patients without autoantibodies against SSA
grouped closer to the healthy controls (Figure 1D), while
patients with EGM (Figure 1E), and patients prescribed
DMARDs or corticosteroids (Figure 1F) grouped throughout
the pSS cluster.
We next analyzed MAPK/ERK and JAK/STAT signaling
networks upon TLR7 and −9 stimulation of PBMC. Initial
responses (15–60min) were weak relative to respective basal
measurements in both T and NK cells, with little or no
change observed in phosphorylation of the measured epitopes
(Figure 2). The strongest initial responses were seen in B
cells for NF-κB, P38, STAT1 S727, and STAT3 S727. The
induction of phosphorylation of STAT1 S727 and STAT3
S727 in B cells from pSS patients was significantly stronger
than healthy donor cells. In order to exclude effects of
the medication on the analyses, we removed medicated
patients from the analyses. This resulted in an even more
pronounced difference between pSS patients and healthy donors
(Supplementary Figure S2).
After 60min of TLR7 and −9 stimulation, many epitopes
of pSS patients displayed altered phosphorylation pattern
compared to healthy donors, independent of medication
(Figure 2, Figure S2).
Next, we included phosphorylation profiles of TLR7 and
−9 stimulated T, NK and B cells in the PCA. Phosphorylation
levels after 15min showed the strongest clustering of subgroups,
while extended time course (>15min) gave no additional
resolution (Supplementary Figure S3), hence we focused on
inducedMdFI at 15min (MdFI15min-MdFIbasal) after stimulation
with TLR7 and 9 ligands (Figure 3). PCA visualization showed
a positive shift along PC1 for approximately half the pSS
samples away from healthy donor samples (Figure 3B). The
pSS samples that were distributed away from the healthy
donors were largely composed of EGM-negative (Figure 3D)
and unmedicated patients (Figure 3E). PC1 explained 83%
of the variation with positive movement along PC1, strongly
influenced by phosphorylation of NF-κB and STAT3 S727 in B
cells (Figure 3A). PC2 explained 9% of the variation and was
influenced primarily by induced phosphorylation of NF-κB in B
cells in a positive direction and negatively by STAT3 S727 in NK,
T and B cells (Figure 3A).
Further comparisons of variables used in the final PCA were
conducted by Mann-Whitney U tests (Figure 3F). Comparisons
between groups and subgroups (pSS patients, healthy donors,
EGM+/–, SSA+/–) were analyzed with and without exclusion
of medicated patients, in order to exclude that the effects
seen were merely due to medication used by patients. EGM–
patients had a significantly increased response to stimulation by
TLR7 and −9 ligands in B cells through NF-κB compared to
EGM+ patients. T cells from EGM-negative patients exhibited
a significantly decreased response in STAT3 S727 compared
to those from EGM+ patients. B cells showed a significantly
increased response in STAT3 S727 in pSS patients compared
to healthy controls, SSA+ compared to SSA– patients and
EGM– patients compared to EGM+ patients. Upon removal of
medicated patients, in particular the B cell phospho-epitopes
for NF-κB, pP38, and STAT3 S727 resulted in stronger and
significant differences between healthy donors and pSS patients
(Supplementary Figure S4).
To summarize, after omitting patients prescribed DMARDs
or corticosteroids from the analysis, B cells from pSS patients
showed an increased response to TLR7 and −9 stimulation
through NF-κB.
Phosphorylation Profiles of Immune Cells
Allow for Stratification of Patient
Subgroups
A subgroup of pSS patients is characterized by a so-called type
I IFN signature that correlates with increased disease activity
(9). We therefore calculated an IFN score using three type I
IFN inducible genes (MxA, OAS, IFI44) according to Feng et al.
(19). As control, two type II IFN inducible genes (GBP1, GBP2)
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FIGURE 1 | Basal phosphorylation profiles in B cells, T cells and NK cells of pSS patients differ compared to healthy controls. Basal phosphorylation levels of NF-κB,
P38, ERK1/2, STAT4 Y693, STAT5 Y694, STAT1 Y701, STAT1 S727, STAT3 Y705, and STAT3 S727 were analyzed by flow cytometry in T cells, B cells and NK cells
are given in (A). Comparisons of phosphorylation levels (MdFI) between healthy donor (blue) and pSS patient (black). Comparisons between pairs were done using an
(Continued)
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FIGURE 1 | Unpaired Mann-Whitney test. Graphs show the median, 25–75 percentiles and minimum and maximum. Differences were considered statistically
significant when p ≤ 0.05, with significance indicated as * ≤ 0.05, ** ≤ 0.01, and **** ≤ 0.0001. PCA analysis of the profiles is given in (B–F), disease status is
highlighted in (C), SSA autoantibody positivity in (D), presence of EGM in (E), and medication (DMARDs or corticosteroids) use in (F), with healthy donors, blue
squares; pSS patients, black circles; SSA+, EGM+, or medicated patients, red diamonds (D–F, respectively). The loading plot, which contains information about the
variable for the corresponding PCA is given in (B), with variable indicated by vectors and the key to the right. Variables contributing little to the PCA are plotted around
the center as denoted by the gray axis, while variables that have high contributions are plotted further from the axes. After initial calculation of principal components,
the model was recalculated with only variable explaining >50% of the variance retained. The data represents 25 healthy controls and 25 patients pooled from 13
independent experiments.
were included. The threshold was set to 8.8 based on 3 × SD of
healthy controls. A type I interferon signature was found in 70%
of patients and 0% of controls (Figure 4A). Medicated patients
tended toward reduced expression compared to unmedicated
patients (Figure 4B).
To investigate whether type I IFN activation was reflective
of phosphorylation levels of intracellular signaling proteins, the
gene expression was correlated to signaling profiles (Figures 4,
5). Comparisons of patients subdivided into type I IFN
signature positive (IFN+) and negative (IFN–) patients and
healthy donors were made for each intracellular signaling
molecule and cell type, with basal phosphorylation variables
that showed the strongest associations with type I IFN gene
expression shown in Figure 4C. Both, IFN+ and IFN– patients
displayed increased phosphorylation of STAT1 S727 in T cells.
Interestingly, an increased phosphorylation of STAT1 Y701 was
detected in NK cells of IFN+ patients compared to IFN–
patients.
Basal phosphorylation levels in B cells from pSS patients
were generally negatively correlated with type I IFN inducible
gene expression, while positively correlated in NK and T cells,
with weaker associations found with type II IFN inducible
gene expression. The strongest significant correlations between
type I IFN regulated genes were observed in NK cells
for pERK, pSTAT1 Y701 and pSTAT3 Y705, and T cells
for pSTAT1 S727 (Figure 4D). No significant associations
were observed against type II IFN regulated genes for the
aforementioned epitopes (Figure 4D).
We next analyzed the phosphorylation status upon TLR7 and
−9 stimulation in correlation to IFN inducible gene expression
in pSS patients against variables identified previously by PCA
(Figure 5A). IFN+ patients showed increased phosphorylation
of NF-κB and STAT3 S727 in B cells, and these differences
remained significant following the removal ofmedicated patients.
No difference was seen between the patient groups for
phosphorylation of STAT3 S727 in T or NK cells.
Especially in B cells a prevalent positive correlation of
phosphorylation levels and IFN inducible gene expression
were detected. The strongest correlations were seen for
phosphorylation levels of NF-κB and STAT3 S727 (Figure 5B).
STAT4 Y693, NF-κB, P38, and STAT3 Y705 in NK cells and
NF-κB in T cells showed positive associations, but only NF-
κB and P38 reached statistical significant correlations. Of the
other two variables identified by PCA, STAT3 S727 in T
and NK cells, no significant correlation with gene expression
was observed (Figure 5B).
Plasma Cytokine Levels Correlate With
Presence of Autoantibodies and Signaling
Responses in Patient Subgroups
The role of cytokines in pSS has been a matter of great interest
over the past few years (25, 26). Our aim was to examine
the plasma cytokine concentration of our pSS patient cohort,
compare them to healthy controls, and possibly correlate them to
clinical parameters and phosphorylation pattern of the epitopes
included in this study.
GM-CSF, IL-5, and IL-8 were excluded from the analyses
as they were below detection limit in most samples analyzed.
Eotaxin, IL-7, IP10, andMIG were not included in the analysis as
they were not recommended to be measured in heparin plasma
by the manufacturer.
When comparing patients with controls, 12 out of the 25
cytokines measured were significantly upregulated in patients
including IL-1ß, IL-13, IL-6, IL-12, MIP-1α, MIP-1ß, MCP-1,
IL-15, IFN-α, TNFα, IL-2, and IL-4 (Supplementary Figure S5,
Supplementary Table S5). When dividing the patients into
subgroups based on the presence or absence of autoantibodies
(SSA+/SSA–), extraglandular manifestations (EGM+/EGM–),
IFN score, medication and Focus score, the only significant
differences were seen in SSA+ patients, where IL-1ß, MCP-1,
IFN-α, IL-2, and IL-4 were significantly upregulated compared
to SSA– patients (Figure 6, Supplementary Table S6).
Correlation analysis of the individual cytokines of the
patients to the phosphoproteins yielded significant results. While
the basal phosphorylation profiles of all the patients showed
only moderate correlations (<0.6) to the plasma cytokine
concentrations, excluding medicated patients from the analysis
resulted in strong to very strong correlations of RANTES to pNF-
κB in NK cells, MIP-1ß, MCP-1, IL-2, and IL-4 to pSTAT5 Y694
in B cells, and IL-1RA to pSTAT1 Y701 in T cells (Figure 7).
We next explored the correlation of the plasma cytokine
levels to basal phosphorylation pattern depending on presence
or absence of SSA and EGM. The exclusion of medicated patients
in the subgroup analysis resulted in too few patients per group
for reliable data, therefore all patients were included in this part
of the analysis. We observed strong to very strong correlations
in SSA+ patients of MIP-1α, IL-1RA, and TNF-α to pSTAT3
Y705 in B cells, TNF-α to pNF-κB in B cells, and RANTES to
pSTAT4 Y693 and pSTAT1 S727 in NK cells (Figure 8A). In
SSA– patients, RANTES correlated to pNF-κB in T cells and
pERK in T cells (Figure 8B). Patients with EGM had strong to
very strong correlations of several cytokines to amongst other
pSTAT4 Y693 in NK (Figure 9A), and RANTES, IFN-γ, IL-1RA,
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FIGURE 2 | TLR stimulation results in different phosphorylation profiles in B cells, T cells, and NK cells of pSS patients compared to healthy controls. Phosphorylation
levels of NF-κB, P38, ERK1/2, STAT4 Y693, STAT5 Y694, STAT1 Y701, STAT1 S727, STAT3 Y705, and STAT3 S727 were analyzed by flow cytometry at different time
points after stimulation with TLR7 and −9 ligands. Comparisons of change of phosphorylation levels (1MdFI) between pSS patient (black) and healthy donors (blue)
are given. Comparisons between pairs were done using an Unpaired Mann-Whitney test. Line graphs show the median and 25–75 percentiles. Differences were
considered statistically significant when p ≤ 0.05, with significance indicated as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 and **** ≤ 0.0001. The data represents 25 healthy
controls and 25 patients pooled from 13 independent experiments.
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FIGURE 3 | PCA analysis of induced phosphorylation in PBMC at 15min following stimulation with TLR 7 and −9 ligands. Groupings of samples by PCA are shown
by disease status (B), SSA autoantibody positivity (C), EGM presence (D), and medication use (DMARDs or corticosteroids) (E). Healthy donor samples are indicated
by blue squares, pSS patients as black circles, and pSS patients with SSA autoantibodies, EGM or using prescribed DMARDs or corticosteroids (C–E, respectively)
displayed as red diamonds. The loading plot, which contains information about the variable for the corresponding PCA is shown in (A), with variables contributing to
the PCA given as vectors. Variables contributing little to the PCA are plotted around the center as denoted by the gray axis, while variables that have high
contributions are plotted further from the axes. After initial calculation of principal components the model was recalculated with only variable explaining >50% of the
variance retained, stepwise reduction of less significant variables with low variable leverage was then performed. Scatter box plots of variable used in PCA for TLR7
and −9 ligand induced responses are given in (F). Figures show change in MdFI from 0 to 15min (Y axis) following addition of TLR7 and −9 ligands to PBMC cultures.
Measured phospho-protein and responding cell type are labeled above each figure. Groups are identified at the base of each figure (X axis), initially with pSS patients
(pSS) and healthy donors (HD Ctrl), pSS patients are further divided into SSA autoantibody positive and negative patients, patients with EGM (EGM+) or without EGM
(EGM–), and unmedicated and medicated patients. Statistical comparisons were made between each of these pairs as indicated by dashed lines, with black bars
representing medians. The data represents 25 healthy controls and 25 patients pooled from 13 independent experiments. Comparison between pairs were conducted
using an Unpaired Mann-Whitney test with significance indicated as * ≤ 0.05, ** ≤ 0.01 and *** ≤ 0.001.
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FIGURE 4 | Associations of the basal phosphorylation profile with type I IFN inducible gene expression in pSS patients and healthy controls. IFN score was calculated
based on standardized expression levels of three type I IFN inducible genes (MxA, OAS1, IFI44). A threshold was set to 8.8 based on 3 × SD of healthy controls as
seen in (A). Association between IFN score and the use of DMARD or corticosteroids is seen in (B). Unpaired Mann-Whitney test comparisons of
(Continued)
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FIGURE 4 | basal phosphorylation levels for IFN+ patients (n = 14), IFN– patients (n = 6), and healthy controls (n = 17) with the strongest associations are given in
(C), with medians indicated by black bars. Comparisons were conducted using an Unpaired Mann-Whitney test. Correlations between three type I IFN inducible genes
(MxA, OAS1, IFI44) and two type II inducible genes (GBP1, GBP2) with basal phosphorylation levels in pSS patients (n = 20) epitopes, as given in (C), is shown in (D).
Correlations were assessed with Spearman’s rank test, with outliers removed using robust regression and outlier removal (ROUT) method and a ROUT coefficient Q of
1 was used. Significant values are indicated as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001. The flow cytometric data represents 17 healthy controls and 20
patients pooled from 13 independent experiments, with real time qPCR data representing a single experiment incorporating the 17 healthy controls and 20 patients.
FIGURE 5 | Associations of the phosphorylation profile 15min after TLR7 and −9 stimulation with IFN inducible gene expression in pSS patients and healthy controls.
(A) Unpaired Mann-Whitney test comparisons of phosphorylation levels after TLR7 and −9 stimulation for IFN signature positive patients (n = 14), IFN signature
negative patients (n = 6) and healthy controls (n = 17), medians are given by black bars. (B) Correlation plots of variable identified by PCA and three type I IFN
inducible genes (MxA, OAS1, IFI44) and two type II IFN inducible gene (GBP1, GBP2) for pSS patients (n = 20). Correlations were assessed with Spearman’s rank
test, with outliers removed using robust regression and outlier removal (ROUT) method and a ROUT coefficient Q of 1 was used. Significant values are indicated as * ≤
0.05 and ** ≤ 0.01. The flow cytometric data represents 17 healthy controls and 20 patients pooled from 13 independent experiments, with real time qPCR data
representing a single experiment incorporating the 17 healthy controls and 20 patients.
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FIGURE 6 | Differential expression of cytokines between autoantibody positive (SSA+) and autoantibody negative (SSA-) pSS patients. Cytokine profiles were
measured by 25-plex Luminex assay in plasma. Cytokine levels (pg/ml) showing significant differences between SSA+ patients (red) and SSA– patients (black) are
shown. Healthy controls (HD Ctrls) are shown in blue. Medicated patients are shown as diamond. Comparison between pairs was done by unpaired Mann-Whitney
test between the two patient subgroups. Differences were considered statistically significant for p ≤ 0.05, with significance being indicated as * ≤ 0.05, ** ≤ 0.01. The
median is indicated. The data represents pSS patients (n = 25) grouped into SSA+ patients (n = 12) and SSA– patients (n = 13) (except for IL-4, n = 11 in each
category).
IFN-α, and IL-12 correlated with various phospho-epitopes in
EGM– patients (Figure 9B).
DISCUSSION
Autoimmune diseases often exhibit skewed cytokine and gene
expression profiles. Elucidating mechanisms that contribute to
these profiles are crucial in understanding the pathogenesis of
autoimmune disease. Of prominent interest in autoimmunity is
an increased expression of type I IFN regulated genes known as
the “interferon signature” which has been observed in various
autoimmune diseases (8, 9, 27, 28). Continuous activation and
dysregulation of TLR and type I IFN signaling have been
speculated to play a part in this signature and pathogenesis of
autoimmune disease (29), and IFN signature positive pSS patients
have been shown to have increased expression of TLR7 in certain
cell types (30). In addition, we have previously shown that PBMC
of pSS patients have an altered response to IFN-α stimulation
(10). Hence we investigated cell signaling profiles in PBMCof pSS
patients upon stimulation via TLR7 and−9, determined the gene
expression profile of several IFN inducible genes and correlated
these findings to plasma cytokine levels.
In accordance with a previous observation we found increased
basal STAT5 Y694 phosphorylation in T cells from pSS patients
compared to healthy donors (31). However, in contrast to our
study, the authors also found significant differences in B cells
for basal phosphorylation of STAT5 Y694 and no differences in
phosphorylation of STAT1 Y701 in T cells (31). Another study
also reported on significant differences in basal phosphorylation
levels of STAT3 Y705 in T cells (32), which also is in contrast to
our findings. However, these differences are likely the result of the
use of cryopreserved PBMC and long culture period (6 h) in our
study, as both other studies used freshly isolated cells.
Although PCA using basal measurements allowed for
grouping of pSS patients and healthy donors, its use to identify
important variables of basal measurements for subgrouping of
the patient cohort was largely unsuccessful. The majority of B
cell associated variables largely correlated with each other, as
did T and NK cells with the grouping of pSS patients being
a consequence of higher basal phosphorylation in T and NK
cells. Even though some differences were seen when dividing
the pSS patients according to medication, the small sample size
limits how much we can speculate on the pathophysiological
significance of this.
Basal STAT1 Y701 in NK cells was increased in type I IFN+
patients, but the difference was no longer significant when
excludingmedicated patients. However, the sample size following
exclusion was relatively low, while the data spread remained
similar. Further, phosphorylation of many of the measured
phospho epitopes in NK and T cells from pSS patients, in
particular STAT1 Y701 in NK cells, were positively correlated
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FIGURE 7 | Correlations of basal phosphorylation profiles with plasma cytokine levels in pSS patients without medication. Correlations were assessed by Spearman’s
rank test. Strong (r = 0.6–0.79) to very strong (r = 0.8–1.0) associations are shown with respective p and r-values given at the side of each graph. Correlations were
considered statistically significant for p ≤ 0.05. X-axis denotes concentration of cytokines (pg/ml) and Y-axis denotes phosphorylation levels (MdFI). The data
represents pSS patients (n = 16) without medication (except for IL-4, n = 14, and RANTES, n = 15).
with the expression levels of the three type I IFN inducible genes,
while in B cells a negative correlation was observed. In contrast,
little relationship was observed for the type II IFN induced
genes. Not much is known about NK cells in Sjögren’s syndrome,
so the correlation with basal phosphorylation of ERK, STAT1
Y701, and STAT3 Y705 in NK cells is especially interesting.
Moreover, levels of several plasma cytokines also correlated with
basal phosphorylation in NK cells. Further studies are required to
confirm these correlations.
Following stimulation with TLR7 and −9 ligands, B
cells from pSS patients showed a significantly increased
STAT3 S727 response compared to healthy donors. After
excluding medicated patients, phosphorylation of NF-κB and
P38 was also significantly elevated in B cells from pSS
patients compared to healthy donors. These findings support
the notion that pSS patients display a hyperactive B cell
response and are in line with our previous study showing
increased expression of IFN-α in B cells from pSS patients
after incubation with TLR7 ligands compared to B cells
from healthy donors (33). The increased response to TLR7
and −9 ligands through these pathways may play a role
in the increased expression of IFN-α from B cells of
pSS patients, and may also contribute to the observed
IFN signature in some pSS patients. Thereby, it opens for
speculations regarding the importance of viral infections for
pSS patients. Further, a number of polymorphisms associated
with pSS and the presence of autoantibodies in pSS could
potentially affect signaling through NF-κB, P38, and STAT3
S727. If the potentiation of these signaling profiles are
associated with polymorphisms in negative regulators of TLR
signaling, including A20 (antiapoptotic signaling protein)
which deubiquitylates TRAF6 (tumor-necrosis factor-receptor-
associated factor 6), and affects both MyD88-dependent and
MyD88-independent pathways (34), these differences will also
likely be reflected in other cell types using the same pathways.
Alternatively, the increased response through these pathways
may be attributed to the cellular effects of induction of type I
IFN gene expression.
Interestingly, 70% of the patients included in this study had
an activated type I IFN system. This is somewhat higher than
previously reported for pSS patients [around 55%; (9)] and SLE
patients [around 50%; (27)]. This might be due to limited sample
size and differences in patient inclusion criteria. However, also
the plasma levels of IFN-α were elevated in our cohort of pSS
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FIGURE 8 | Correlation of basal phosphorylation status with plasma cytokine levels in pSS patients grouped according to autoantibody status. Autoantibody positive
pSS patients (SSA+) (A), autoantibody negative pSS patients (SSA–) (B). Correlations were assessed by Spearman’s rank test. Medicated patients are shown in red
while un-medicated patients are shown in black. Strong (r = 0.6–0.79) to very strong (r = 0.8–1.0) associations are shown with respective p and r-values given at the
side of each graph. Associations were considered statistically significant for p ≤ 0.05. X-axis denotes concentration of cytokines (pg/ml) and Y-axis denotes
phosphorylation levels (MdFI). The data represents pSS patients (n = 25) grouped into SSA+ patients (n = 12) (except for RANTES, n = 11) and SSA–
patients (n = 13).
patients, especially in SSA+ patients, which might explain the
high percentage of IFN+ patients.
Induced phosphorylation of STAT3 S727, NF-κB, and P38
correlated significantly with type I IFN inducible gene expression.
Type I IFN has been shown to enhance B cell responses to TLR7
ligands and upregulate TLR7 and MyD88 expression in naïve B
cells (35, 36). Increased type I IFN gene expression may therefore
act to potentiate these signals.
Systemic autoimmune diseases are associated with the
production of autoantibodies and have an important role in
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FIGURE 9 | Correlation of basal phosphorylation profiles with plasma cytokine levels in pSS patients grouped according to the presence of extraglandular
manifestations (EGM). Extraglandular manifestation positive pSS patients (EGM+) (A) and extraglandular manifestation negative pSS patients (EGM–) (B). Correlations
were assessed by Spearman’s rank test. Medicated patients are shown in red while un-medicated patients are shown in black. Strong (r = 0.6–0.79) to very strong
(r = 0.8–1.0) associations are shown with respective p and r-values given at the side of each graph. Associations were considered statistically significant for p ≤ 0.05.
X-axis denotes concentration of cytokines (pg/ml) and Y-axis denotes phosphorylation levels (MdFI). The data represents pSS patients (n = 25) grouped into EGM+
patients (n = 14) (except for IL-4, n = 11) and EGM– patients (n = 11).
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the immunopathogenesis of various autoimmune diseases (29).
Animal models have indicated links between TLR recognizing
nucleic acids and the production of nucleic acid recognizing
antibodies (37). Additionally, type I IFN inducible gene
expression has been observed to positively correlate with
titers of SSA and SSB autoantibodies in SS (38). We showed
increased responses of B cells from SSA+ pSS patients through
phosphorylation of STAT3 S727 in response to TLR7 and −9
stimulation compared to SSA– patients. Our study thereby
links all three observations, enhanced TLR7 and −9 responses,
increased type I IFN gene expression and autoantibodies, further
highlighting their importance in autoimmunity.
Principal component analysis suggests that it is possible to
subdivide pSS patients based on presence of EGM. EGM negative
patients displayed enhanced TLR responses through NF-κB, P38,
and STAT3 S727 in B cells compared to EGM+ patients. This was
also seen after removal of patients prescribed the glucocorticoid
prednisone, which has been reported to inhibit NF-κB activation
(39), and hydroxychloroquine (Plaquenil R©) inhibiting TLR7 and
−9 signaling (40). However, it is still surprising that it was the
EGM negative patients that had an enhanced response in B cells,
as a number of EGM in SS are associated with high prevalence
of hyperreactive B-cells as well as SSA and SSB autoantibodies
(41). One possible explanation might be that the lower responses
of B cells from EGM+ patients represent movement of more
reactive B cells from the periphery to other compartments not
being analyzed in this study.
Several plasma cytokines correlated significantly with basal
phosphorylation levels of various phospho-epitopes in T-, B-,
and NK cells. However, even though presence of outliers was
tested using ROUT’s method, most outliers detected by the test
were not excluded from the analyses except a few very obvious
ones, as Rout’s method is not very reliable for non-parametric
data. The low number of patients per subgroup further requires
caution concerning interpretation of the data. A larger number
of patients has to be analyzed before a more reliable correlation
between phosphorylation pattern, cytokine profile, presence of
autoantibodies and EGM might be found. This might also help
clarifying the pathophysiological relevance of our findings.
This study has a number of limitations, for one, small
sample size, which is further affected by the heterogeneity
of the patients, and in particular the number of medicated
patients. Second, as this was a pilot study, the analysis was
limited to the three main subsets of lymphocytes (T, B, and
NK cells). As these cell subsets are made up of numerous
other subtypes, differential responses and shifts in their relative
frequency in the peripheral blood may affect cellular responses.
Immunophenotyping studies have shown altered distribution
of various cell types in peripheral blood (42, 43). We can
therefore not be certain that the changed signaling profiles
are not caused by these alterations rather than potentiated or
repressed signaling. Moreover, certain subpopulations might be
more prone to apoptosis upon longer stimulation with TLR7
and −9 ligands, which we did not address in this study.
Finally the type I and II IFN regulated gene expression was
assessed in PBMC, and assessment for each cell type might
have strengthened associations and be more informative in
determining origin of the signature. In addition, some of the
statistically significant differences were rather small. Future
studies will have to address the biological relevance in more
functional assays.
In conclusion, we have identified increased responses by B
cell from pSS patients to TLR7 and −9 stimulation through
STAT3 S727 and NF-κB. The increased response was found to
correlate to a type I IFN signature. The results suggest that the
type I IFN signature may either induce or in part be derived
in response to increased activation of NF-κB and STAT3 S727
upon TLR7 or −9 activation, facilitating increased production
of interferon.
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